Takeda Pharmaceutical Co Ltd (4502.T)
23 Mar 2018
Fri, Mar 23 2018
BRIEF-Tigenix And Takeda Announce Alofisel® (Darvadstrocel) Receives Approval To Treat Complex Perianal Fistulas In Crohn's Disease In Europe
* TIGENIX AND TAKEDA ANNOUNCE ALOFISEL® (DARVADSTROCEL) RECEIVES APPROVAL TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE IN EUROPE
BRIEF-Riken Vitamin says Takeda Pharmaceutical to decrease voting power in co to 5.4 pct from 12.6 pct
* Says Takeda Pharmaceutical Co Ltd will decrease voting power in the company to 5.4 percent(881,760 shares) from 12.6 percent(2.1 million shares), effective Feb. 27
BRIEF-Wave Life Sciences And Takeda Form Strategic Collaboration To Advance Therapies For Central Nervous System Disorders
* WAVE LIFE SCIENCES AND TAKEDA FORM GLOBAL STRATEGIC COLLABORATION TO ADVANCE THERAPIES FOR CENTRAL NERVOUS SYSTEM DISORDERS
* Hikes full-year op profit outlook to 219 bln yen from 200 bln
TOKYO Takeda Pharmaceutical Co Ltd said its annual profit will outstrip a prior estimate and reach a six-year high, boosted by stronger sales of the cancer drug Velcade, after earlier reporting better-than-expected quarterly earnings.
TOKYO, Feb 1 Takeda Pharmaceutical Co Ltd , Japan's largest drugmaker by sales, on Thursday reported an almost 60 percent jump in quarterly operating profit and raised its annual forecast, citing stronger sales of cancer drug Velcade.
Japan's Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted 'fast track' status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
Jan 29 Japan's Takeda Pharmaceutical Co Ltd said on Monday the U.S. Food and Drug Administration had granted 'fast track' status to its vaccine for the mosquito-borne Zika virus, which erupted as a major public hazard in Brazil three years ago.
* TAKEDA’S ZIKA VACCINE CANDIDATE RECEIVES U.S. FDA FAST TRACK DESIGNATION
CHICAGO New dengue vaccines being developed by Takeda Pharmaceuticals Co Ltd and U.S. government scientists are poised to provide a safer alternative to Sanofi's Dengvaxia, according to vaccine experts, because they already take into account some of the issues that sidelined the product last year.